Antibiotic resistance is the public-health driver behind much of the antimicrobial peptide pipeline. Carbapenem-resistant gram-negatives, MRSA, biofilm-producing organisms, and persister cells are the priority pathogens that small-molecule antibiotics are losing ground against.
Programs covered on this site include Peptilogics on prosthetic-joint biofilm, Fedora Pharmaceuticals' FPI-2119 lactivicin against gram-negatives, work on Acinetobacter baumannii (e.g., Barnards' neonatal sepsis program), and Longhorn Vaccines' DRG5-BD11 peptidoglycan platform. HMD-AMP discovery work from HLB Innovation also lands here.
Stories here cover the candidates, the WHO and CDC guideline updates that frame the policy fight, and the reimbursement obstacles that keep slowing AMP commercialization. See #amr and #antimicrobial-peptide for adjacent threads.
A January 2026 Frontiers in Cellular and Infection Microbiology review synthesized the case for antimicrobial peptides (AMPs) as the most promising response to antimicrobial resistance, which is responsible for nearly 5 million deaths annually and projected to double by 2050. The review emphasizes that AMPs' rapid, multi-target mechanism — primarily physical membrane disruption — produces significantly lower incidence of resistance emergence than traditional small-molecule antibiotics. The pipeline now exceeds 150 active candidates spanning AI-designed AMPs, lysin-derived peptides, and venom-derived sequences.
Findings from the Oxford-led BARNARDS II study presented at ESCMID Global 2026 showed WHO-recommended ampicillin plus gentamicin first-line therapy is likely effective for only 1 in 4 neonatal sepsis infections in low- and middle-income countries. Data were collected across 13 tertiary neonatal units in Pakistan, Bangladesh, and Nigeria from February 2024 to October 2025, intensifying the case for AMR-driven peptide alternatives.
A Nature Communications paper published April 15 reveals shared structural mechanisms between SbmA — an E. coli membrane transporter that imports antimicrobial peptides — and ABC transporters. Using cryo-electron microscopy, EPR spectroscopy, and molecular dynamics simulations, researchers demonstrated SbmA undergoes ABC-transporter-like conformational changes, informing strategies to design antibiotic-resistant-bacteria-penetrating peptide drugs.
A study in Nature Microbiology used a generative protein language model (ProteoGPT) to discover novel antimicrobial peptides effective against multidrug-resistant bacteria. The AI-designed peptides showed comparable or superior efficacy to clinical antibiotics in mouse infection models, with reduced resistance development and no organ damage.
A study published in Nature Microbiology used a generative AI approach to discover antimicrobial peptides effective against multidrug-resistant bacteria. The deep learning pipeline screened millions of candidate sequences, achieving a 94.4% success rate in lab validation, with two candidates showing exceptional efficacy and low resistance potential.